Genmab — Januar 2021

[E_L]

https://www.prnewswire.com/news-releases/johnson--johnson-reports-2020-fourth-quarter-and-full-year-results-301214853.html

[E_L]

1253

[Bulder]

det er ok

[E_L]

=692 US
+561 ROW

[E_L]

SO 4190=2232+1958

[Bulder]

Very close to guiding top

[JørgenVarnæs]

US surprisingly high - RoW surprisingly low

[Solsen]

Ok citi var for optimistiske

[GeorgeBest]

Thanks, ROW a bit dissapoiting

[Solsen]

Faspro=ketchupeffekt

[Bulder]

Yes faspro is the reason for us-row difference

[Bulder]

But all in all ok numbers

[Bulder]

Corona taken in concideration

[StockBull]

Hvad mon de guider for 2021 / formoder vi skal over 5mia eller 5.5 ?

[JørgenVarnæs]

fun fact - in Q3 the prescription/sales ratio was 88%. In Q4 the ratio was 92%

[JørgenVarnæs]

Faspro must be selling without discount

[Bulder]

Jeg tror på 5,5 mia i 2021. Især hvis corona klinger af i row

[E_L]

yes, rather remarkable

[GeorgeBest]

Corona klinger vel først af i Q3, men mener ogsà 5,5 mia er et godt gæt. Amyloidosis vil give et stort skub

[E_L]

@Bulder agree; in the Netherlands 100,000 surgical procedures are delayed atm due to corona, i assume that hospital pressure is roughly the same all over europe. Wonder what the numbers would have been without corona...